Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 5;23(1):121.
doi: 10.1186/s12933-024-02219-w.

Association between triglyceride-glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation

Sixiang Jia #  1 , Yanping Yin #  2   3 , Xuanting Mou #  1 , Jing Zheng  1   4 , Zhe Li  1 , Tianli Hu  1 , Jianqiang Zhao  1 , Jiangbo Lin  2   3 , Jiaqi Song  5 , Fanli Cheng  1 , Yiran Wang  1 , Kaini Li  1 , Wenting Lin  1 , Chao Feng  1 , Weili Ge  6   7 , Shudong Xia  8
Affiliations

Association between triglyceride-glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation

Sixiang Jia et al. Cardiovasc Diabetol. .

Abstract

Background: This study investigates the relationship between triglyceride-glucose (TyG) index trajectories and the results of ablation in patients with stage 3D atrial fibrillation (AF).

Methods: A retrospective cohort study was carried out on patients who underwent AF Radiofrequency Catheter Ablation (RFCA) at the Cardiology Department of the Fourth Affiliated Hospital of Zhejiang University and Taizhou Hospital of Zhejiang Province from January 2016 to December 2022. The main clinical endpoint was determined as the occurrence of atrial arrhythmia for at least 30 s following a 3-month period after ablation. Using a latent class trajectory model, different trajectory groups were identified based on TyG levels. The relationship between TyG trajectory and the outcome of AF recurrence in patients was assessed through Kaplan-Meier survival curve analysis and multivariable Cox proportional hazards regression model.

Results: The study included 997 participants, with an average age of 63.21 ± 9.84 years, of whom 630 were males (63.19%). The mean follow-up period for the participants was 30.43 ± 17.75 months, during which 200 individuals experienced AF recurrence. Utilizing the minimum Bayesian Information Criterion (BIC) and the maximum Entropy principle, TyG levels post-AF RFCA were divided into three groups: Locus 1 low-low group (n = 791), Locus 2 low-high-low group (n = 14), and Locus 3 high-high group (n = 192). Significant differences in survival rates among the different trajectories were observed through the Kaplan-Meier curve (P < 0.001). Multivariate Cox regression analysis showed a significant association between baseline TyG level and AF recurrence outcomes (HR = 1.255, 95% CI: 1.087-1.448). Patients with TyG levels above 9.37 had a higher risk of adverse outcomes compared to those with levels below 8.67 (HR = 2.056, 95% CI: 1.335-3.166). Furthermore, individuals in Locus 3 had a higher incidence of outcomes compared to those in Locus 1 (HR = 1.580, 95% CI: 1.146-2).

Conclusion: The TyG trajectories in patients with stage 3D AF are significantly linked to the outcomes of AF recurrence. Continuous monitoring of TyG levels during follow-up may help in identifying patients at high risk of AF recurrence, enabling the early application of effective interventions.

Keywords: Atrial fibrillation recurrence; Insulin resistance; Radiofrequency catheter ablation; Triglyceride–glucose index trajectory.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study flow chart
Fig. 2
Fig. 2
The trajectory trend chart
Fig. 3
Fig. 3
K‒M survival curve
Fig. 4
Fig. 4
Subgroup forest graph
Fig. 5
Fig. 5
The predictive value of each indicator
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Writing Committee Members, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol. 2024;83(1):109–279. doi: 10.1016/j.jacc.2023.08.017. - DOI - PMC - PubMed
    1. Brundel BJJM, Ai X, Hills MT, Kuipers MF, Lip GYH, de Groot NMS. Atrial fibrillation. Nat Rev Dis Primers. 2022;8(1):21. doi: 10.1038/s41572-022-00347-9. - DOI - PubMed
    1. Lip GY, Fauchier L, Freedman SB, Van Gelder I, Natale A, Gianni C, Nattel S, Potpara T, Rienstra M, Tse HF, Lane DA. Atrial fibrillation. Nat Rev Dis Primers. 2016;2:16016. doi: 10.1038/nrdp.2016.16. - DOI - PubMed
    1. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. doi: 10.1136/bmj.i4482. - DOI - PubMed
    1. Choi SE, Sagris D, Hill A, Lip GYH, Abdul-Rahim AH. Atrial fibrillation and stroke. Expert Rev Cardiovasc Ther. 2023;21(1):35–56. doi: 10.1080/14779072.2023.2160319. - DOI - PubMed

Publication types